| dc.contributor.author | Keiner, Elizabeth S. | |
| dc.contributor.author | Slaughter, James C. | |
| dc.contributor.author | Datye, Karishma A. | |
| dc.contributor.author | Cherrington, Alan D. | |
| dc.contributor.author | Moore, Daniel J. | |
| dc.contributor.author | Gregory, Justin M. | |
| dc.date.accessioned | 2023-02-02T20:33:10Z | |
| dc.date.available | 2023-02-02T20:33:10Z | |
| dc.date.issued | 2022-10 | |
| dc.identifier.issn | 0149-5992 | |
| dc.identifier.other | eISSN 1935-5548 | |
| dc.identifier.other | PubMed ID35944264 | |
| dc.identifier.uri | http://hdl.handle.net/1803/17975 | |
| dc.description.abstract | OBJECTIVE Although mortality from coronavirus disease 2019 (COVID-19) among youth with type 1 diabetes is rare, severe acute respiratory syndrome coronavirus 2 is associated with increased pediatric hospitalizations for diabetic ketoacidosis (DKA). To clarify whether the relationship between COVID-19 and DKA is coincidental or causal, we compared tissue glucose disposal (TGD) during standardized treatment for DKA between pediatric patients with COVID-19 and those without COVID-19.
RESEARCH DESIGN AND METHODS We retrospectively compared TGD during standardized therapy for DKA in all children with preexisting type 1 diabetes with or without COVID-19. Cases were assessed beginning with the first case of COVID-19-positive DKA on 19 June 2020 through 2 February 2022.
RESULTS We identified 93 COVID-19-negative patients and 15 COVID-19-positive patients who were treated for DKA, with similar baseline characteristics between groups. Median TGD was 46% lower among patients who had COVID-19 compared with those who did not (P = 0.013).
CONCLUSIONS These results suggest that COVID-19 provokes a metabolic derangement over and above factors that typically contribute to pediatric DKA. These findings underscore the significant and direct threat posed by COVID-19 in pediatric type 1 diabetes and emphasize the importance of mitigation and monitoring including through vaccination as a primary prevention. | en_US |
| dc.description.sponsorship | Research and personnel for this publication were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award nos. K23DK123392 (J.M.G.) and R01DK121316 (K.A.D.). The research was also supported by a pilot and feasibility grant from the Vanderbilt Diabetes Research and Training Center (DK020593). J.M.G was supported by a JDRF Career Development Award (5-ECR-2020-950-A-N). K.A.D. was supported by the Katherine Dodd Faculty Scholars Program.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the JDRF. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Diabetes Care | en_US |
| dc.rights | This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article.
Requests to reprint or otherwise use any American Diabetes Association logos or servicemarks must be addressed by American Diabetes Association's Permissions Division. Please email details of your request to permissions@diabetes.org. | |
| dc.source.uri | https://diabetesjournals.org/care/article/45/10/2406/147406/COVID-19-Exacerbates-Insulin-Resistance-During | |
| dc.subject | Glucose | en_US |
| dc.title | COVID-19 Exacerbates Insulin Resistance During Diabetic Ketoacidosis in Pediatric Patients With Type 1 Diabetes | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.2337/dc22-0396 | |
